B-cell prolymphocytic leukemia: Difference between revisions
Jump to navigation
Jump to search
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Infobox_Disease | {{Infobox_Disease | ||
| Name = {{PAGENAME}} | | Name = {{PAGENAME}} | ||
Line 15: | Line 16: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 26: | Line 25: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
{{jb1}} | {{jb1}} |
Revision as of 17:00, 12 September 2012
B-cell prolymphocytic leukemia | |
ICD-O: | 9833 |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
B-cell prolymphocytic leukemia is a more aggressive, but still treatable, form of chronic lymphocytic leukemia. The malignant B cells are larger than average. The name is commonly abbreviated B-PLL.
It can involve deletions from chromosome 11 and chromosome 13.[1]
It has a relatively poor prognosis.[2]
References
- ↑ Lens D, Matutes E, Catovsky D, Coignet LJ (2000). "Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL)". Leukemia. 14 (3): 427–30. PMID 10720137.
- ↑ Del Giudice I, Davis Z, Matutes E; et al. (2006). "IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)". Leukemia. 20 (7): 1231–7. doi:10.1038/sj.leu.2404238. PMID 16642047.